131 related articles for article (PubMed ID: 9873879)
21. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status.
Seremetis SV; Aledort LM; Bergman GE; Bona R; Bray G; Brettler D; Eyster ME; Kessler C; Lau TS; Lusher J
Lancet; 1993 Sep; 342(8873):700-3. PubMed ID: 8103820
[TBL] [Abstract][Full Text] [Related]
22. [Effect of factor VIII concentrates of very high purity on CD4+ cell count in hemophiliacs infected with HIV].
Molina Alejandro R; Lorenzo Herrero JI; Haya Guaita S; Querol Fuentes F; Aznar Lucea JA
Rev Clin Esp; 1996 Jun; 196(6):365-9. PubMed ID: 8767071
[TBL] [Abstract][Full Text] [Related]
23. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
Mannucci PM
Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
[TBL] [Abstract][Full Text] [Related]
24. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
[TBL] [Abstract][Full Text] [Related]
25. Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y).
Evans JA; Pasi KJ; Williams MD; Hill FG
Br J Haematol; 1991 Nov; 79(3):457-61. PubMed ID: 1751373
[TBL] [Abstract][Full Text] [Related]
26. Lymphocyte subset ratios and factor VIII usage in haemophilia.
Beddall AC; Al-Rubei K; Williams MD; Hill FG
Arch Dis Child; 1985 Jun; 60(6):530-6. PubMed ID: 3925894
[TBL] [Abstract][Full Text] [Related]
27. Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97.
Yee TT; Pasi KJ; Lilley PA; Lee CA
Br J Haematol; 1999 Mar; 104(4):909-14. PubMed ID: 10192458
[TBL] [Abstract][Full Text] [Related]
28. Five year prospective study of HIV infection in the Edinburgh haemophiliac cohort.
Cuthbert RJ; Ludlam CA; Tucker J; Steel CM; Beatson D; Rebus S; Peutherer JF
BMJ; 1990 Oct; 301(6758):956-61. PubMed ID: 1979015
[TBL] [Abstract][Full Text] [Related]
29. Comparison of immunodeficiency and AIDS defining conditions in HIV negative and HIV positive men with haemophilia A.
Sabin CA; Pasi KJ; Phillips AN; Lilley P; Bofill M; Lee CA
BMJ; 1996 Jan; 312(7025):207-10. PubMed ID: 8563582
[TBL] [Abstract][Full Text] [Related]
30. Who should receive recombinant factor VIII?
Giangrande PL
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
[TBL] [Abstract][Full Text] [Related]
31. Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapy.
Cuthbert RJ; Ludlam CA; Steel CM; Beatson D; Peutherer JF
Br J Haematol; 1992 Mar; 80(3):364-9. PubMed ID: 1581216
[TBL] [Abstract][Full Text] [Related]
32. High purity factor VIII concentrates for the treatment of HIV-positive patients with haemophilia.
Sultan Y
Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S80-1. PubMed ID: 7495974
[TBL] [Abstract][Full Text] [Related]
33. Effect of high- versus intermediate-purity blood coagulation factor concentrates on HIV-1 replication.
Schögl D; Zimmermann K; Turecek PL; Schwarz HP; Eibl MM; Mannhalter JW
Vox Sang; 1996; 70(4):195-7. PubMed ID: 9123922
[TBL] [Abstract][Full Text] [Related]
34. Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia A.
Klamroth R; Simpson M; von Depka-Prondzinski M; Gill JC; Morfini M; Powell JS; Santagostino E; Davis J; Huth-Kühne A; Leissinger C; Neumeister P; Bensen-Kennedy D; Feussner A; Limsakun T; Zhou M; Veldman A; St Ledger K; Blackman N; Pabinger I
Haemophilia; 2016 Sep; 22(5):730-8. PubMed ID: 27434619
[TBL] [Abstract][Full Text] [Related]
35. Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion.
Touloumi G; Karafoulidou A; Gialeraki A; Katsarou O; Milona I; Kapsimali V; Mandalaki T; Hatzakis A
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Sep; 19(1):89-97. PubMed ID: 9732075
[TBL] [Abstract][Full Text] [Related]
36. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
Zollner S; Raquet E; Claar P; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2014 Jul; 134(1):125-31. PubMed ID: 24814969
[TBL] [Abstract][Full Text] [Related]
37. Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII-SingleChain and other common rFVIII products in Germany.
Olivieri M; Sommerer P; Maro G; Yan S
Eur J Haematol; 2020 Apr; 104(4):310-317. PubMed ID: 31883398
[TBL] [Abstract][Full Text] [Related]
38. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project.
Fischer K; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Iorio A; Gilman E; Makris M;
Thromb Haemost; 2015 May; 113(5):968-75. PubMed ID: 25567324
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of a monoclonal purified factor VIII concentrate: 5-year follow-up in previously treated HIV-negative haemophiliacs.
Smid WM; van der Meer J; Halie MR
Haemostasis; 1995; 25(5):229-36. PubMed ID: 7489961
[TBL] [Abstract][Full Text] [Related]
40. Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Transfusion Safety Study Group.
Gjerset GF; Pike MC; Mosley JW; Hassett J; Fletcher MA; Donegan E; Parker JW; Counts RB; Zhou Y; Kasper CK
Blood; 1994 Sep; 84(5):1666-71. PubMed ID: 7915149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
